Brief: Ascletis Pharma Inc Says FY Revenue RMB40.4 Million
20/03/2023 01:02
March 20 (Reuters) - Ascletis Pharma Inc 1672.HK :
* FY REVENUE RMB40.4 MILLION VERSUS RMB70.9 MILLION
* FY LOSS ATTRIBUTABLE RMB314.8 MILLION VERSUS LOSS OF
RMB199.0
MILLION
Source text for Eikon: ID:
Further company coverage: 1672.HK
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Ascletis Pharma
See all newsAscletis hits 4-week high on initiating US Phase I study on obesity drug
Brief: Ascletis Pharma Initiates U.S. Phase I Study For ASC36 Oral Tablets For Obesity
Brief: Ascletis Pharma Inc. Says Board Of Directors Does Not Recommend Payment Of Any Dividend In Respect Of HY
China's Ascletis Pharma H1 net loss widens on higher R&D costs
Brief: Ascletis Announces First Participant Dosed In A Global Phase III Clinical Program Of Once-Daily Oral Small Molecule Glp-1 Receptor Agonist ASC30 For Chronic Weight Management